ZA202108217B - Lipid-based nanoparticles and use of same in optimized insulin dosing regimens - Google Patents
Lipid-based nanoparticles and use of same in optimized insulin dosing regimensInfo
- Publication number
- ZA202108217B ZA202108217B ZA2021/08217A ZA202108217A ZA202108217B ZA 202108217 B ZA202108217 B ZA 202108217B ZA 2021/08217 A ZA2021/08217 A ZA 2021/08217A ZA 202108217 A ZA202108217 A ZA 202108217A ZA 202108217 B ZA202108217 B ZA 202108217B
- Authority
- ZA
- South Africa
- Prior art keywords
- lipid
- same
- dosing regimens
- based nanoparticles
- insulin dosing
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833228P | 2019-04-12 | 2019-04-12 | |
| US202062988748P | 2020-03-12 | 2020-03-12 | |
| PCT/US2020/027762 WO2020210697A1 (en) | 2019-04-12 | 2020-04-10 | Lipid-based nanoparticles and use of same in optimized insulin dosing regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202108217B true ZA202108217B (en) | 2023-12-20 |
Family
ID=72748579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/08217A ZA202108217B (en) | 2019-04-12 | 2021-10-25 | Lipid-based nanoparticles and use of same in optimized insulin dosing regimens |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10918700B2 (https=) |
| EP (1) | EP3952904A4 (https=) |
| JP (1) | JP2022526842A (https=) |
| AU (1) | AU2020271901A1 (https=) |
| CA (1) | CA3136665A1 (https=) |
| WO (1) | WO2020210697A1 (https=) |
| ZA (1) | ZA202108217B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| JP7306718B2 (ja) * | 2017-03-13 | 2023-07-11 | エスディージー インコーポレイテッド | 向上した安定性を有する脂質ベースのナノ粒子 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863896A (en) * | 1984-05-03 | 1989-09-05 | Technology Unlimited, Inc. | Diabetic control by combined insulin forms |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| ES2124303T3 (es) | 1992-03-25 | 1999-02-01 | Depomed Inc | Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa. |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| EP1087753A4 (en) * | 1998-05-19 | 2004-06-30 | Sdg Inc | TARGETED LIPOSOMAL DRUG ADMINISTRATION SYSTEM |
| HK1050135A1 (zh) | 1999-11-02 | 2003-06-13 | Depomed, Inc. | 用於促进将药物给予胃的饭後模式药理学诱导 |
| DE60123384T2 (de) | 2000-02-04 | 2007-08-02 | DepoMed, Inc., Menlo Park | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| MXPA03011096A (es) | 2001-05-29 | 2004-12-06 | Depomed Dev Ltd | Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna. |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| DE50209996D1 (de) * | 2001-11-16 | 2007-05-31 | Medinnovation Ag | Medizinische pumpvorrichtung |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| EP1858545A2 (en) | 2005-03-04 | 2007-11-28 | Curedm Inc. | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
| US20110135725A1 (en) | 2005-05-23 | 2011-06-09 | Sdg, Inc. | Lipid Construct for Delivery of Insulin to a Mammal |
| US20100129428A1 (en) * | 2005-05-23 | 2010-05-27 | Sdg, Inc. | Supra molecular construct for delivery of interferon to a mammal |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| TWI614024B (zh) * | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US20120035105A1 (en) * | 2009-01-09 | 2012-02-09 | Sdg, Inc. | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments |
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| JP7306718B2 (ja) | 2017-03-13 | 2023-07-11 | エスディージー インコーポレイテッド | 向上した安定性を有する脂質ベースのナノ粒子 |
| EP3483629B1 (en) * | 2017-11-09 | 2021-12-29 | Veoneer Sweden AB | Detecting a parking row with a vehicle radar system |
| KR20200106912A (ko) | 2018-01-05 | 2020-09-15 | 에스디지,인코포레이티드 | 당뇨병을 치료하기 위한 지질 기반 나노입자를 포함하는 조성물 |
-
2020
- 2020-04-10 CA CA3136665A patent/CA3136665A1/en active Pending
- 2020-04-10 US US16/846,101 patent/US10918700B2/en active Active
- 2020-04-10 AU AU2020271901A patent/AU2020271901A1/en not_active Abandoned
- 2020-04-10 EP EP20788205.1A patent/EP3952904A4/en active Pending
- 2020-04-10 JP JP2021559986A patent/JP2022526842A/ja active Pending
- 2020-04-10 WO PCT/US2020/027762 patent/WO2020210697A1/en not_active Ceased
-
2021
- 2021-01-19 US US17/151,980 patent/US20210379160A1/en not_active Abandoned
- 2021-10-25 ZA ZA2021/08217A patent/ZA202108217B/en unknown
-
2023
- 2023-05-22 US US18/321,429 patent/US20240139288A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022526842A (ja) | 2022-05-26 |
| EP3952904A4 (en) | 2022-12-28 |
| EP3952904A1 (en) | 2022-02-16 |
| AU2020271901A1 (en) | 2021-11-04 |
| US20240139288A1 (en) | 2024-05-02 |
| US20210379160A1 (en) | 2021-12-09 |
| US10918700B2 (en) | 2021-02-16 |
| WO2020210697A1 (en) | 2020-10-15 |
| CA3136665A1 (en) | 2020-10-15 |
| US20200323961A1 (en) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500680A1 (en) | Compositions and methods of use for treating metabolic disorders | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| PH12017500153B1 (en) | Compositions and methods of use for treating metabolic disorders | |
| MY208231A (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| WO2012014074A3 (en) | Motion compensation for non-invasive treatment therapies | |
| PH12016501978B1 (en) | Treatment of nafld and nash | |
| EA201890382A1 (ru) | Конструкции антител для cd70 и cd3 | |
| WO2014138429A3 (en) | Peptidomimetic macrocycles and use thereof in regulating hif1alpha | |
| SG10201808259TA (en) | Anti-jagged1 antibodies and methods of use | |
| MX2019000088A (es) | Composiciones y metodos para detectar y tratar la diabetes. | |
| MY191321A (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| PH12017500052A1 (en) | Myo-inositol and probiotics and uses | |
| ZA202108217B (en) | Lipid-based nanoparticles and use of same in optimized insulin dosing regimens | |
| EP3648762A4 (en) | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED DISEASES | |
| MX385029B (es) | Una combinacion de vitamina d y zinc y su uso. | |
| AU2018262805A1 (en) | Peptides for treatment of diabetes | |
| MX2020007067A (es) | Composiciones que comprenden nanoparticulas a base de lipidos para el tratamiento de la diabetes mellitus. | |
| MX2020003531A (es) | Soluciones de templado reactivo y metodos de uso. | |
| MX2019011297A (es) | Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo. | |
| PH12015501607A1 (en) | Coated shaped metal material | |
| MX2021004531A (es) | Nuevos usos. | |
| MX2018001493A (es) | Gdf-15 como biomarcador de toxicidad hematologica. | |
| PH12019550033A1 (en) | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan | |
| PH12017500084A1 (en) | Vitamin b2 and its use |